Involvement and role of antidepressant drugs of the hypothalamic-pituitary-adrenal axis and glucocorticoid receptor function

Neuroendocrinology Letters

Volumn 30, Issue 1, 2009, Pages 11-16

  Nikisch, Georg ^a  

^a KLINIKUM FULDA   (Germany)

Author keywords

Antidepressants; Depression; Glucocorticoid receptors; Hypothalamic pituitary adrenal axis; Stress

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CORTICOTROPIN RELEASING FACTOR; DESIPRAMINE; FLUOXETINE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMIPRAMINE; LITHIUM; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; OXAPROTILINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; ZIMELDINE;

BRAIN REGION; CUSHING SYNDROME; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; ELECTROCONVULSIVE THERAPY; HORMONE RELEASE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MAJOR DEPRESSION; MONOAMINERGIC SYSTEM; NEGATIVE FEEDBACK; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION;

ANTIDEPRESSIVE AGENTS; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MOOD DISORDERS; PITUITARY-ADRENAL SYSTEM; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTION, GENETIC;

EID: 65349129516     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. 1 agonists in the rat. Neuroendocrinology. 50: 241-247.
2. Beaulieu S, Pelletier G, Vaudry H, Barden N (1989). Influence of the central nucleus of the amygdala on the content of corticotrophin-releasing factor in the median eminence. Neuroendocrinology. 49: 255-261.
3. Beaulieu S, De Paolo T, Côté J, Barden N (1987). Participation of the central amygdaloid nucleus in the response of adrenocorticotropin secretion to immobilization stress: opposing roles of the noradrenergic and dopaminergic systems. Neuroendocrinology. 45: 37-46.
4. Binnemann B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger TH (2008). A 6-week randomized, placebo-controlled trail of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry. 165: 617-620.
5. Bradbury MJ, Akana SF, Cascio CS, Levin N, Jacobson L, Dallman MF (1991). Regulation of basal ACTH secretion by corticosterone is mediated by both type I (MR) and type II (GR) receptors in rat brain. J Steroid Biochem Mol Biol. 40: 133-142.
6. Brady LS, Whitfield HJ, Fox RJ, Gold PW, Herkenham M (1991). Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. J Clin Invest. 87: 831-837.
7. Budziszewska B, Jaworska-Feil L, Kajta M, Lasoñ W (2000). Antidepressant drugs inhibit glucocorticoid receptor-mediated gene transcription - a possible mechanism. Brit J Pharmacol. 130: 1385-1393.
8. Budziszewska B, Siwanowicz J, Przegaliñski E (1994). The effect of chronic treatment with antidepressant drugs on the corticosteroid receptor levels in the rat hippocampus. Pol J Pharmacol. 46: 147-152.
9. Carroll BJ, Curtis GC, Mendels J (1976). Neuroendocrine regulation in depression I. Limbic system-adrenocortical dysfunction. Arch Gen Psychiatry. 33: 1039-1050.
10. Cascio CS, Shinsako J, Dallman MF (1987). Ihe suprachiasmatic nuclei stimulate evening ACTH secretion in the rat. Brain Res. 423: 173-179.
11. Cintra A, Zoli M, Rosen L, Agnati LF, Okret S, Wikstrom AC, et al (1994). Mapping and computer assisted morphometry and microdensitometry of glucocorticoid receptor immunoreactive neurons and glial cells in the rat central nervous system. Neuroscience. 62: 843-897.
12. Coppen AJ, Doogan DP (1988). Serotonin and its place in the etiopathogenesis of depression. J Clin Psychiat. 49: 4-11.
13. Dallman MF, Levin N, Cascio CS, Akana SF, Jacobson L, Kuhn RW (1989). Pharmacological evidence that the inhibition of diurnal adrenocorticotropin secretion by corticosteroids is mediated via type I corticosterone-preferring receptors. Endocrinology. 124: 2844-2850.
14. de Bellis MD, Gold PW, Geracioti TD.Jr., Listwak SJ, Kling MA (1993). Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiat. 150: 656-657.
15. de Kloet ER (1991). Brain corticosteroid receptor balance and homeostatic control. Front Neuroendocrinol. 12: 95-164.
16. Dunn AJ, Berridge CW (1990). Physiological and behavioral responses to corticotropin-releasing factor administration: Is CRF a mediator of anxiety or stress responses? Brain Res Rev. 15: 71-100.
17. Elliott E, Sapolsky R (1991). Glucocorticoids, neurotoxicity and calcium regulation. In: Costa E, Paul SM, editors. Neurosteroids and Brain Function. New York: Thieme Medical Publishers.
18. Erhardt A, Müller MB, Rödel A, Welt T, Ohl F, Holsboer F et al (2009). Consequences of chronic social stress on behaviour and vasopressin gene expression in the PVN of DBA/2OIaHsd mice-influence of treatment with the CRHR1-antagonist R121919/NBI 30775. J Psychopharmacol. 23: 31-39.
19. Funder JW (1994). Corticosteroid receptors and the central nervous system. J Steroid Biochem Mol Biol. 49: 381-384.
20. Gold PW, Loriaux DL, Roy A (1986). Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. N Engl J Med. 314: 1329-1335.
21. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerinos P, et al (1984). Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Pyschiatry. 141: 619-627.
22. Heuser IJE, Schweiger U, Gotthardt U, Schmider J, Lammers CH, Dettling M, et al (1996). Pituitary-adrenal system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiat. 153: 93-99.
23. Holsboer F, Ising M (2008). Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol. 583: 350-357.
24. Holsboer F, Barden N (1996). Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Rev. 17: 187-205.
25. Holsboer F, Spengler D, Heuser I (1992). The role of corticotrophin releasing hormone in the pathogenesis of Cushing's disease, anorexia nervosa, alcoholism, affective disorders and dementia. In: Swaab DF, Hofman MA, Mirmiran M, Ravid R, van Leeuwen FW, editors. Progress in brain research. Amsterdam: Elsevier.
26. Holsboer F, Gerken A, von Bardeleben U, Grimm W, Beyer H, Müller OA, et al (1986). Human corticotropin-releasing hormone in depression. Biol Psychiatry. 21: 601-611.
27. Holsboer F, Gerken A, Stalla GK, Müller OA (1985). ACTH, cortisol and corticosterone output after ovine corticotropin-releasing factor challenge during depression and after recovery. Biol Psychiatry. 20: 276-286.
28. Holsboer F, von Bardeleben U, Gerken A, Stalla GK, Müller OA (1984). Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor (h-CRF) in depression. N Engl J Med. 311: 1127.
29. Itoi K, Horiba N, Tozawa F, Sakai Y, Sakai K, Abe K, et al (1996). Major role of 3′5′-cyclic adenosine monophosphate-dependent protein kinase. A pathway in corticotropin-releasing factor gene expression in the rat hypothalamus in vivo. Endocrinology. 137: 2389-2396.
30. Jackson IM, Luo LG (1998). Antidepressants inhibit the glucocorticoid stimulation of thyrotropin releasing hormone expression in cultured hypothalamic neurons. J Invest Med. 46: 470-474.
31. Jacobson L, Sapolsky A (1991). The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev. 12: 118-134.
32. Jasper MS, Engeland WC (1994). Splanchnic neural activity modulates ultradian and circadian rhythms in adrenocortical secretion in awake rats. Neuroendocrinology. 59: 97-109.
33. 2 receptor-mediated wet-dog shake behaviors. Psychopharmacology. 108: 27-32.
34. Legradi G, Holzer D, Kapcala LP, Lechan AM (1997). Glucocorticoids inhibit stress-induced phosphorylation of CREB in corticotropin-releasing hormone neurons of the hypothalamic paraventricular nucleus. Neuroendocrinology. 66: 86-97.
35. Linkowski P, Kerkhofs M, Van Onderbergen A, Hubain P, Copinschi G, l'Hermite-Baleriaux M, et al (1994). The 24-hour profiles of cortisol, prolactin, and growth hormone secretion in mania. Arch Gen Psychiatry. 51: 616-624.
36. Lisansky J, Peake GT, Strassman RJ, Qualls C, Meikle AW, Risch C, et al (1989). Augmented pituitary corticotropin response to a threshold dosage of human corticotropin-releasing hormone in depressives pre-treated with metyrapone. Arch Gen Psychiatry. 46: 641-649.
37. Lowy MT, Gault L, Yamamoto BK (1993). Adrenalectomy attenuates stress-induced elevations in extracellular glutamate concentrations in the hippocampus. J Neurochem. 61: 1957-1960.
38. Maccari S, Le Moal M, Angelucci L, Mormede P (1990). Influence of 6-OHDA lesion of central noradrenergic systems on corticosteroid receptors and neuroendocrine responses to stress. Brain Res. 533: 60-65.
39. Magarinos AM, Verdugo JM, McEwen BS (1997). Chronic stress alters synaptic terminal structure in hippocampus. Proc Nat Acad Sci USA. 94: 14002-14008.
40. 1A receptor mRNA in rat dentate gyrus. Eur J Pharmacol. 266: 255-261.
41. Mitchell JB, Rowe W, Boksa P, Meaney MJ (1990). Serotonin regulates type II corticosteroid receptor binding in hippocampal cell cultures. J Neurosci. 10: 1745-1752.
42. Montkowski A, Barden N, Wotjak C, Stec I, Ganster J, Meaney M, et al (1995). Long-term antidepressant treatment reduces behavioural deficits in transgenic mice with impaired glucocorticoid receptor function. J Neuroendocrinol. 7: 841-845.
43. Murphy BE (1991). Steroids and depression. J Steroid Biochem Mol Biol. 38: 537-559.
44. Murphy BEP (1997). Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology. 22: 125-132.
45. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M (1988). Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry. 45: 577-579.
46. Nemeroff CB, Widerlov E, Bisette G, Walléus H, Karlson I, Eklund K, et al (1984). Elevated concentrations of CSF corticotrophin releasing factor-like immunoreactivity in depressed patients. Science. 226: 1342-1343.
47. Nibuya M, Morinobu S, Duman RS (199S). Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 15: 7539-7547.
48. Nikisch G, Ågren H, Eap CB, Czernik A, Baumann P, Mathé AA (2005a). Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol. 8: 403-410.
49. Nikisch G, Czernik A, Thiele J, Bohner J, Eap CB, Mathé AA, et al (2005b). Long-term citalopram administration reduces responsiveness of HPA axis in patients with major depression: relationship with S-citalopram concentrations in plasma and CSF and clinical response. Psychopharmacology. 4: 751-760.
50. Owens MJ, Nemeroff CB (1991). Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev. 43: 425-473.
51. Pariante CM, Miller AH (2001). Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol. Psychiat. 49: 391-404.
52. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH (1997). Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol. 52: 571-581.
53. Peiffer A, Veilleux S, Barden N (1991). Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology. 16: 505-515.
54. Pepin MC, Pothier F, Barden N (1992a). Impaired glucocorticoid receptor function in transgenic mice expressing antisense RNA. Nature. 355: 725-728.
55. Pepin MC, Govindan MV, Barden N (1992b). Increased glucocorticoid receptor gene promoter activity after antidepressant treatment. Mol Pharmacol. 41: 1016-1022.
56. Pepin MC, Beaulieu S, Barden N (1989). Antidepressants regulate glucocorticoid receptor messenger RNA concentrations in primary neuronal cultures. Mol. Brain Res. 6: 77-83.
57. Przegaliñski E, Budziszewska B (1993a). The effect of long-term treatment with antidepressant drugs on the hippocampal mineralocorticoid and glucocorticoid receptors in rats. Neurosci Lett. 161: 215-218.
58. Przegaliñski E, Budziszewska B, Siwanowicz J, Jaworska L (1993b). The effect of repeated combined treatment with nifedipine and antidepressant drugs or electroconvulsive shock on the hippocampal corticosteroid receptors in rats. Neuropharmacology. 32: 1397-1400.
59. Raadsheer FC, Hoogendijk WJG, Stam FC, Tilders FJH, Swaab DF (1994). Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology. 60: 436-444.
60. Ratka A, Sutanto W, Bloemers M, de Kloet ER (1989). On the role of brain mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation. Neuroendocrinology. 50: 117-223.
61. Regestein QR, Rose LI, Williams GH (1972). Psychopathology in Cushing's syndrome. Arch Intern Med. 130: 114-117.
62. Reul JMHM, de Kloet ER (1985). Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology. 117: 2505-2512.
63. Rossby SP, Nalepa I, Huang M, Burt A, Perrin C, Schmidt DE, et al (1995). Norepinephrine-independent regulation of GRII mRNA in vivo by a tricyclic antidepressant. Brain Res. 687: 79-82.
64. Rousse I, Beaulieu S, Rowe W, Meaney MJ, Barden N, Rochford J (1997). Spatial memory in transgenic mice with impaired glucocorticoid receptor function. Neuro Report. 8: 841-845.
65. Schwaninger M, Schofl C, Blume R, Rossig L, Knepel W (1995). Inhibition by antidepressant drugs of cyclic AMP response element-binding protein/ cyclic AMP response element-directed gene transcription. Mol Pharmacol. 47: 1112-1118.
66. Seckl JR, Fink G (1992). Antidepressants increase glucocorticoid and mineralocorticoid receptor mRNA expression in rat hippocampus in vivo. Neuroendocrinology. 55: 621-626.
67. Siegel RA, Weidenfeld J, Chen M (1983). Hippocampal cell nuclear binding of corticosterone following 5,7-dihydroxytryptamine. Mol Cell Endocrinol. 31: 253-259.
68. Szafarczyk A, Alonso G, Ixart G, Malaval F, Assenmacher I (1985). Diurnal-stimulated and stress-induced ACTH release in rats is mediated by ventral noradrenergic bundle. Am J Physiol. 249: 219-226.
69. von Bardeleben U, Holsboer F (1989). Cortisol response to a combined dexamethasone-human corticotropin-releasing hormone challenge in patients with depression. J Neuroendocrinol. 1: 485-488.
70. von Bardeleben U, Stalla GK, Müller OA, Holsboer F (1988). Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pre-treatment. Biol Psychiatry. 24: 782-786.
71. Watanabe Y, Gould E, Daniels DC, Cameron H, McEwen BS (1992). Tianeptine attenuates stress-induced morphological changes in the hippocampus. J Pharmacol. 222: 157-162.
72. Young AH, MacDonald LM, St John H, Dick H, Goodwin GM (1992). The effects of corticosterone on 5-HT receptor function in rodents. Neuropharmacology. 31: 433-438.